Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 11:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Acute Graft Rejection Clear all
Completed No phase listed Observational

T-SPOT.CMV and T-SPOT.PRT Diagnostic Assays

NCT02382211
View directory record Official record
Conditions
Infection in Solid Organ Transplant Recipients
Interventions
Not listed
Lead sponsor
Oxford Immunotec
Industry
Eligibility
18 Years to 75 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
35
States / cities
Tucson, Arizona • Irvine, California • Loma Linda, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Jul 23, 2026, 11:25 AM EDT
Completed Phase 4 Interventional Results available

Comparison of Sirolimus and Azathioprine in Lung Transplantation

NCT00321906
View directory record Official record
Conditions
Delayed Graft Function, Acute Graft Rejection
Interventions
azathioprine, sirolimus
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 20, 2016 · Synced Jul 23, 2026, 11:25 AM EDT
Completed Not applicable Interventional Results available

The Effect of Rituximab on the Development of Anti-Donor Antibodies

NCT00695097
View directory record Official record
Conditions
Renal Transplant Rejection
Interventions
Rituximab, No Rituximab
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
2
States / cities
Birmingham, Alabama • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 25, 2014 · Synced Jul 23, 2026, 11:25 AM EDT
Not listed Phase 1Phase 2 Interventional

Evaluating Safety and Efficacy of TOL101 Induction Versus Anti-Thymocyte Globulin to Prevent Kidney Transplant Rejection

NCT01154387
View directory record Official record
Conditions
End Stage Renal Disease, Renal Transplant
Interventions
Anti-Thymocyte Globulin, TOL101, Steroids, Tacrolimus, Mycophenolate mofetil (MMF)
Drug
Lead sponsor
Tolera Therapeutics, Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
12
States / cities
Aurora, Colorado • Lexington, Kentucky • Ann Arbor, Michigan + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2013 · Synced Jul 23, 2026, 11:25 AM EDT
Completed Phase 4 Interventional Results available

Stress Cardiac MRI for Evaluation of Nonspecific Allograft Dysfunction

NCT02597543
View directory record Official record
Conditions
Heart Transplant, Acute Graft Rejection, Chronic Graft Rejection
Interventions
Regadenoson, Gadolinium, Cardiac MRI
Drug · Procedure
Lead sponsor
Paul Kim
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2017 · Synced Jul 23, 2026, 11:25 AM EDT
Completed Phase 2Phase 3 Interventional

Rituximab for Pediatric Renal Transplant Rejection

NCT00697996
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Rituximab for transplant rejection
Drug
Lead sponsor
Stanford University
Other
Eligibility
5 Years to 21 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 22, 2008 · Synced Jul 23, 2026, 11:25 AM EDT
Terminated Not applicable Interventional Results available

Magnetic Resonance Elastography of Cardiac Transplant Rejection

NCT02266914
View directory record Official record
Conditions
Acute Graft Rejection
Interventions
Magnetic Resonance Elastography driver
Device
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced Jul 23, 2026, 11:25 AM EDT
Completed No phase listed Observational

VIRTUUS Children's Study

NCT03719339
View directory record Official record
Conditions
Renal Transplant Rejection, Pediatric Kidney Disease, End Stage Renal Disease, Nephropathy, BK Virus (Nephropathy), Antibody-mediated Rejection, Acute Cellular Graft Rejection
Interventions
Not listed
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Years to 18 Years
Enrollment
445 participants
Timeline
2017 – 2026
U.S. locations
12
States / cities
La Jolla, California • Los Angeles, California • Palo Alto, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 23, 2026, 11:25 AM EDT
Completed Phase 2 Interventional Results available

A Pilot Study to Evaluate the Use of C1 Esterase Inhibitor (Human) in Patients With Acute Antibody-Mediated Rejection

NCT01147302
View directory record Official record
Conditions
Graft Rejection
Interventions
Placebo, C1 Esterase Inhibitor (Human)
Biological
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Jul 23, 2026, 11:25 AM EDT
Completed Phase 2 Interventional Results available

Randomized Trial for Mixed Acute Rejection

NCT00771875
View directory record Official record
Conditions
Graft Rejection
Interventions
Rabbit Antithymocyte Globulin (RATG), Rituximab, Bortezomib, Acetaminophen, Antihistamine, Methylprednisolone
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 26, 2016 · Synced Jul 23, 2026, 11:25 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection

NCT00300274
View directory record Official record
Conditions
Graft Rejection
Interventions
everolimus, mycophenolate mofetil, cyclosporine, corticosteroids
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
721 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
26
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2012 · Synced Jul 23, 2026, 11:25 AM EDT
Recruiting Phase 4 Interventional

Allograft Dysfunction in Heart Transplant

NCT03102125
View directory record Official record
Conditions
Heart Transplant Failure and Rejection
Interventions
Regadenoson
Drug
Lead sponsor
Paul Kim
Other
Eligibility
18 Years and older
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Jul 23, 2026, 11:25 AM EDT
Recruiting No phase listed Observational

Proteogenomic Monitoring and Assessment of Kidney Transplant Recipients

NCT01531257
View directory record Official record
Conditions
Acute Rejection (AR) of Transplanted Kidney, Chronic Allograft Nephropathy (CAN), Interstitial Fibrosis (IF), Tubular Atrophy (TA)
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jul 23, 2026, 11:25 AM EDT
Active, not recruiting No phase listed Observational

Highly Suppressive Treg in Delayed and Slow Graft Function After Kidney Transplantation

NCT04414111
View directory record Official record
Conditions
DGF, Kidney Transplant; Complications
Interventions
Highly suppressive Treg measurement
Diagnostic Test
Lead sponsor
St. Louis University
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
San Bernardino, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Jul 23, 2026, 11:25 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

HEARTBiT: Multi-Marker Blood Test for Acute Cardiac Transplant Rejection

NCT03575910
View directory record Official record
Conditions
Heart Transplant Failure and Rejection, Heart Failure, Heart Diseases, Heart Failure，Congestive, Transplant; Failure, Heart, Transplant Failure
Interventions
Not listed
Lead sponsor
University of British Columbia
Other
Eligibility
19 Years and older
Enrollment
196 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Jul 23, 2026, 11:25 AM EDT
Completed Phase 2 Interventional Results available

Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignancies

NCT00079391
View directory record Official record
Conditions
Hematologic Malignancies, Bone Marrow Transplant Rejection
Interventions
allogeneic hematopoietic stem cell transplantation
Device
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 25, 2015 · Synced Jul 23, 2026, 11:25 AM EDT
Completed Phase 2 Interventional

An Open-label, Prospective, Randomized, Multi-center, Phase II Comparative Trial of Thymoglobulin Versus Simulect for the Prevention of Delayed Graft Function and Acute Allograft Rejection in Renal Allograft Recipients.

NCT00235300
View directory record Official record
Conditions
Cadaveric Donor Renal Transplantation, Acute Renal Allograft Rejection, Induction Therapy
Interventions
Thymoglobulin [Anti-thymocyte Globulin (rabbit)], Simulect (basliximab)
Biological · Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Jul 23, 2026, 11:25 AM EDT
Completed Phase 2 Interventional Results available

Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant

NCT00096161
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Graft Versus Host Disease, Hodgkin Lymphoma, Myelodysplastic/Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Plasma Cell Myeloma, Waldenstrom Macroglobulinemia
Interventions
Cyclosporine, Mycophenolate Mofetil, Pentostatin, Therapeutic Allogeneic Lymphocytes
Drug · Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2015
U.S. locations
4
States / cities
Salt Lake City, Utah • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 30, 2020 · Synced Jul 23, 2026, 11:25 AM EDT
Recruiting No phase listed Observational

Dd-cfDNA and Treg in Prediction of Kidney Transplant Acute Rejection

NCT05084768
View directory record Official record
Conditions
Acute Rejection of Renal Transplant, Graft Failure
Interventions
Donor-derived cell-free DNA
Diagnostic Test
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Jul 23, 2026, 11:25 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Prospective Lung Transplant Database for Genetic Research

NCT00339209
View directory record Official record
Conditions
Lung Transplantation Rejection
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
18 Years to 80 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
2
States / cities
Durham, North Carolina • Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 23, 2026, 11:25 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.

NCT01598987
View directory record Official record
Conditions
Renal Function, Liver Transplant
Interventions
Introduction of everolimus with reduced cyclosporine or tacrolimus dose, the earliest 1 month and the latest 6 months after liver transplantation.
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Month to 17 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
9
States / cities
Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Jul 23, 2026, 11:25 AM EDT
Terminated No phase listed Observational

Myocardial Perfusion Echocardiography to Detect Human Heart Transplant Rejection

NCT02300870
View directory record Official record
Conditions
Heart Transplantation
Interventions
Optison
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Jul 23, 2026, 11:25 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Tolerability and Safety of Early Introduction of Everolimus, Reduced Calcineurin Inhibitors and Early Steroid Elimination Compared to Standard CNI, Mycophenolate Mofetil and Steroid Regimen in Paediatric Renal Transplant Recipients

NCT01544491
View directory record Official record
Conditions
Prevention of Acute Rejection in Paediatric Recipients of a Renal Transplant
Interventions
RAD001, MMF
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Year to 18 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
3
States / cities
Los Angeles, California • Ann Arbor, Michigan • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 30, 2019 · Synced Jul 23, 2026, 11:25 AM EDT
Terminated No phase listed Observational

Personalization of Immunosuppressive Treatment for Organ Transplant Recipients

NCT05747053
View directory record Official record
Conditions
Kidney Injury, Kidney Failure, Kidney Failure, Chronic, Kidney Failure, Acute, Kidney Diseases, Kidney Transplant Rejection, Kidney Transplant Infection, Kidney Transplant; Complications, Kidney Disease, Chronic, Kidney Ischemia
Interventions
AlloSure, PAXGene
Diagnostic Test
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 80 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 25, 2024 · Synced Jul 23, 2026, 11:25 AM EDT